What anticoagulant therapy is required after stenting in patients with atrial fibrillation?

Anticoagulant and antiplatelet therapy are recommended after percutaneous coronary intervention in patients with atrial fibrillation. Current recommendations call for antiplatelet therapy to be discontinued 1 year after implantation of a drug-eluting stent (DES), due to excessive bleeding risk. But randomized clinical trials are lacking to validate this recommendation. The ADAPT AF-DES clinical trial is a multicenter, prospective, open-label, randomized, non-inferiority trial involving 960 patients with atrial fibrillation. Patients included in the study are randomized to receive either a non-vitamin K antagonist oral anticoagulant monotherapy, or combination therapy with clopidogrel.